To access this material please log in or register

Register Authorize

Review of studies on the enalapril treatment in patients with chronic heart failure

Mareev Yu. V.
Federal State Budgetary Institution, "Russian Cardiology Scientific and Production Center" of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: bioequivalency, generic, ACE inhibitors, prognosis, heart failure

DOI: 10.18087/rhfj.2015.1.2056

Chronic HF is a common manifestation of various cardiac abnormalities, which is characterized by high mortality. The up-to-date concept for treatment of CHF, influencing neuro-humoral systems, is related with introduction of ACE inhibitors to clinical practice. The review focuses on studies using one of the first ACE inhibitors, enalapril, in patients with CHF. The author also discussed studies comparing bioequivalency, stability and clinical equivalency of the original enalapril (renitec) and its generics.
  1. Braunwald E. The management of heart failure: the past, the pre­sent and the future. Circ Heart Fail. 2008 May;1 (1):58–62.
  2. Katz AM. The «modern» view of heart failure: how did we get here? Circ Heart Fail. 2008 May;1 (1):63–71.
  3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987 Jun 4;316 (23):1429–35.
  4. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999 Jan;20 (2):136–9.
  5. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991 Aug;325 (5):293–302.
  6. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992 Sep 3;327 (10):685–91.
  7. Jong P, Yusuf S, Rousseau MF et al. Effect of enalapril on 12‑year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003 May 31;361 (9372):1843–8.
  8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003 Mar;22 (2):151–85.
  9. Dighe SV. A review of the safety of generic drugs. Transplant Proc. 1999 May;31 (3A Suppl): 23S-4S.
  10. Якусевич В. В. Качественное лекарственное средство: каким оно должно быть. Рациональная Фармакотерапия в Кардиологии. 2006;2 (4):41–6.
  11. Моисеев С. В. Кордарон или амиодарон в лечении и профилактике аритмий? Клиническая Фармакология и Терапия. 2010;17 (3):18–22.
  12. Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of gene­ric and brand-name drugs used in cardiovascular disease: a syste­matic review and meta-analysis. JAMA. 2008 Dec 3;300 (21):2514–26.
  13. Kesselheim AS. The backlash against bioequivalence and the interchangeability of brand-name and generic drugs. CMAJ. 2011 Sep 6;183 (12):1350–1.
  14. Lopes RA, Neves Fde A. Meta-analysis for bioequivalence stu­dies: interchangeability of generic drugs and similar containing Hydrochlorothiazide is possible but not with Enalapril Maleate. J Bras Nefrol. 2010 Apr-Jun;32 (2):173–81.
  15. United States Pharmacopeia 27‑National formulary 22, United States Pharmacopeial Convention, Rockville, 2004. Available at: http://www.usp.org / usp-nf
  16. Lima DM, dos Santos LD, Lima EM. Stability and in vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications. J Pharm Biomed Anal. 2008 Aug 5;47 (4-5):934–7.
  17. World health organization. Good distribution practices (gdp) for pharmaceutical products. Working document QAS / 04.068 / Rev.2:1–28. Available at: http://www.who.int / medicines / services / expertcommittees / pharmprep / QAS_068Rev2_GDPdraft.pdf
  18. Остроумова О. Д., Бондарец О. В., Шорикова Е. Г. Действитель­но ли дешевле лечить больных артериальной гипертензией генерическими препаратами? Справочник поликлинического врача. 2009;4:16–9.
  19. Боброва О. П., Петрова М. М. Сравнение фармакокинетических и фармакодинамических показателей оригинального и воспроизведенного эналаприла при лечении артериальной гипертонии у лиц старческого возраста, Рациональная Фармакотерапия в Кардиологии. 2012;8 (2):149–53.
  20. Тарловская Е. И., Баландина Ю. А., Сапожникова И. Е., Максимчук Н. С. Сравнительная эффективность комбинирован­ной антигипертензивной терапии у пациентов с умеренной артериальной гипертензией и сахарным диабетом 2 типа. Рациональная Фармакотерапия в Кардиологии. 2011;7 (6):703–7.
Mareev Yu. V. Review of studies on the enalapril treatment in patients with chronic heart failure. Russian Heart Failure Journal. 2015;16 (1):52–56

To access this material please log in or register

Register Authorize
Ru En